Xeris Biopharma (XERS) Stock Price & Analysis

XERS$16.97+0.35 +2.11%
BiotechnologyGrowth StockHigh Quality
Compare
Market cap$3.10BEnterprise value$3.2BRevenue (TTM)$368.26MMarket position—

Score

65
Bullish
Value
32
Quality
70
Growth
94

AI Analysis

Snapshot

Xeris Biopharma Holdings is a growth-led story right now — Growth 94/100 is the pillar doing the heavy lifting (overall 65/100) in Biotechnology. Under the hood: revenue compounding ~39% annually over recent years. Street targets still imply ~12% below the current price.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

32
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

94
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

70
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Xeris Biopharma Holdings, Inc. (XERS) last printed $16.97. Equity value is $3.10B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$1.07M$1.56M$2.46M$2.72M$20.43M$49.59M$110.25M$163.91M$203.07M$291.85M

About

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Xeris Biopharma (XERS) Stock Price & Analysis

XERS price $16.97 +0.35 +2.11%

Ticker
XERS
Price
$16.97
Change
+0.35 +2.11%
Market cap
$3.10B
Forward P/E
42.07
Dividend yield
0.00%
Beta
0.84
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
65
Value
32
Quality
70
Growth
94

Stocklytics score rationale: value 32, quality 70, growth 94.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener